2025 Partners
Take a Look at Our 2025 Partners
Tempus
Lead Partner
Tempus is making precision medicine a reality through the power and promise of data and artificial intelligence. Tempus offers companion diagnostic development across our portfolio of assays, leveraging a broad-panel, a universal platform used by thousands of oncologists globally. These assays can each incorporate multiple companion diagnostic markers, providing value across biopharma portfolios.
Turbine
Expertise Partner
What if you could predict therapy response using patient-representative avatars before you test in the wet lab? Turbine trains avatars and simulates billions of in silico experiments in weeks across all stages of drug development. This approach helps identify the most promising therapeutic combinations and predict which patients will benefit from DDR-related therapies. For more information, please visit www.turbine.ai
ANGLE
Innovation Partner
ANGLE’s innovative circulating tumour cell (CTC) DDR pharmacodynamic biomarker assays, γH2AX, pKAP1, RAD51 and micronuclei, can detect even low levels of DNA damage, making them reliable biomarkers in clinical research. Our GCP-compliant service and R&D laboratories provide biomarker screening services and can develop DDR-specific biomarker assays tailored to your needs. Our patented FDA cleared Parsortix® technology ensures superior CTC liquid biopsy analysis for use in DDR clinical trials.
IntoDNA
Innovation Partner
IntoDNA provides its proprietary STRIDE technology for highly sensitive, direct, in situ detection of DNA damage. STRIDE combined with comprehensive solutions and expertise supports groups that develop DDR targeted therapies. The technology can be applied to a variety of biological materials at any stage of the drug development pipeline to enrich biopharmaceutical research.
Oncolines
Innovation Partner
Oncolines B.V., a subsidiairy of Symeres in the Netherlands, is a precision medicine services company in oncology and cancer immunotherapy. We offer a set of complementary services to enable our clients to determine the activity, selectivity and mechanism of action of drugs and drug candidates.
Our technology platforms comprise cancer cell panel profiling, drug combination testing, bioinformatics, flow cytometry, sequencing, generation of drug resistant cell lines and biochemical assays, such as target residence time measurement.
